Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety measures for the second cohort of its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to evaluate the company’s novel drug to treat concussion: PRV-002. During the trial, healthy human subjects received the drug in order to determine its safety; for all cohorts of the trial, PRV-002 was found to be safe and was well tolerated. The company stated that during phase 1 of the MAD trial, 16 trial participants received PRV-002, with cohort 1, which consists of eight individuals, receiving a low dose of the drug, and cohort 2, which consists of eight additional individuals, receiving a higher dose of the drug. The company is now moving forward on plans for phase II of the trial, and is choosing clinical sites and preparing an investigator’s brochure. “At double the dose of the previous cohort, we saw no serious adverse events,” said Odyssey Health CEO Michael Redmond in the press release. “As we come close to completing the phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment, PRV-002. I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting.”
To view the full press release, visit https://ibn.fm/D6KJs
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility and have a substantial market opportunity. For more information about the company, please visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
